drugset
drugset / Trial / NCT06713499

A Phase Ib/II Study to Investigate the Safety of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis

NCT06713499 ↗

Phase 1/2 Completed 51 enrolled Guangdong Hengrui Pharmaceutical Co., Ltd
NaSingle-groupOpen-labelTreatment

Summary

This trial was designed to evaluate the safety of SHR-1819 in children and adolescents with moderate-to-severe atopic dermatitis.

Timeline

Start
2024-12-18
Primary completion
2025-11-22
Completion
2025-11-22

Drugs

EvaluationDrugModalityDoseRoute
Subject SHR-1819 Monoclonal antibody — —

Indications

atopic eczema